Results 91 to 100 of about 35,471,860 (258)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

The Underlying Mechanisms of Chinese Herbal Medicine-Induced Apoptotic Cell Death in Human Cancer

, 2020
The high incidence of cancer is a global burden. Cancer cells acquire immortality, which results in loss of control in cell proliferation and population expansion.
Feiyu Chen, Yibin Feng, Zhong, Z, Wang, N, Feng, Y, Tan, HYH, Ning Wang, Zhangfeng Zhong, Hor Yue Tan, Chen, F   +9 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Monocytes regulate the mechanism of T-cell death by inducing Fas-mediated apoptosis during bacterial infection. [PDF]

, 2012
Monocytes and T-cells are critical to the host response to acute bacterial infection but monocytes are primarily viewed as amplifying the inflammatory signal.
Mitchell, T.J., Timothy J. Mitchell (150478), Moira K. B. Whyte (150482), David H. Dockrell (114218), Read Robert C., Daigneault, Marc, Daigneault Marc, De Silva, T.I., Helen M. Marriott (150472), De Silva Thushan I., Marriott, Helen M, Preston, Julie A, Dockrell, David H, Marriott, H.M., Julie A Preston, Thushan I. De Silva, De Silva, Thushan I., Dockrell, David H., Whyte, M.K.B., Martin A. Bewley, Preston, Julie A., Mitchell Timothy J., Andrea M. Mitchell, Timothy J Mitchell, Whyte, Moira K B, Mitchell Andrea M., Thushan I. De Silva (150466), Moira K. B. Whyte, Preston Julie A., Helen M Marriott, Preston, J.A., Martin A. Bewley (150467), Robert C Read, Bewley, M.A., Marc Daigneault (150463), Marc Daigneault, Dockrell, D.H., Mitchell, Andrea M; id_orcid, Whyte Moira K. B., Whyte, Moira K. B., Marriott Helen M., Mitchell, Andrea M., Read, Robert C., Robert C. Read (145234), De Silva, Thushan I, Mitchell, Timothy J., Read, R.C., David H. Dockrell, Julie A. Preston (150469), Andrea M. Mitchell (150475), Mitchell, Timothy J, David H Dockrell, Moira K B Whyte, Marriott, Helen M., Mitchell, A.M., Timothy J. Mitchell, Andrea M Mitchell, Bewley, Martin A, Daigneault, M., Read, Robert C, Robert C. Read, Dockrell David H., Bewley, Martin A., Martin A Bewley, Helen M. Marriott, Julie A. Preston, Dockrell, David, Bewley Martin A., Thushan I De Silva   +68 more
core   +1 more source

The Role of Programmed Cell Death Receptor 1 in Lung Cancer. [PDF]

In Vivo, 2022
Badiu DC, Zgura A, Mehedintu C, Haineala B, Anghel R, Bacinschi X.   +5 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

, 2013
Peer ...
Garry M. Walsh, Walsh, Garry M
core   +1 more source

D-1 Gene Polymorphism in Salivary Gland Tumors

Journal of Dental School, 2019
Objectives This study aimed to assess PD-1gene polymorphism in salivary gland tumors in patients referred to Khalili Hospital in Shiraz. Methods This case-control study evaluated 48 patients with salivary gland tumors and 100 age- and sex-matched ...
Jannan Ghapanchi, Behnam Samavatian, Hamid Ghaderi, Bijan Khademi, Elham Mahmoudi Maymand, Elaheh Ainy   +5 more
doaj   +1 more source

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China. [PDF]

Front Immunol, 2023
Hong Y, Song M, Lan Y, Wang J, Lu S, Zhang Y, Zhu J, Sun F, Huang J, Liu J, Xu J, Wu Y, Guo H, Cai R, Zhen Z, Que Y, Zhang Y.   +16 more
europepmc   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source